Vera Therapeutics, Inc. $VERA Stock Acquired by Candriam S.C.A.

Key Points

• Candriam increased its Vera Therapeutics stake by 21.5% in the third quarter, adding 100,461 shares to reach 568,560 shares valued at about $18.4 million. Institutional investors collectively own 99.21% of the company.
• Vera’s third-quarter results beat analyst estimates: its loss was $1.30 per share versus an expected $1.62, while revenue was $10.28 million against forecasts of $3.42 million.
• Analyst views are mixed: the stock has a “Moderate Buy” consensus and an average price target of $74.93, though several firms recently lowered their targets and Wedbush assigned a neutral rating.

Candriam S.C.A. lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 21.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 568,560 shares of the company's stock after buying an additional 100,461 shares during the period. Candriam S.C.A. owned approximately 0.79% of Vera Therapeutics worth $18,426,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in VERA. Sterling Capital Management LLC increased its position in Vera Therapeutics by 841.5% in the 3rd quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $68,000 after acquiring an additional 1,885 shares during the period. Nykredit A S acquired a new stake in Vera Therapeutics during the 2nd quarter worth approximately $97,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Vera Therapeutics in the 3rd quarter valued at approximately $119,000. Strs Ohio purchased a new position in shares of Vera Therapeutics in the 1st quarter valued at approximately $249,000. Finally, NINE MASTS CAPITAL Ltd purchased a new position in shares of Vera Therapeutics in the 2nd quarter valued at approximately $405,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Vera Therapeutics Price Performance

Shares of VERA opened at $29.78 on Monday. Vera Therapeutics, Inc. has a twelve month low of $23.86 and a twelve month high of $56.05. The stock's 50 day moving average is $31.60 and its two-hundred day moving average is $36.68. The firm has a market capitalization of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.62) by $0.32. The business had revenue of $10.28 million for the quarter, compared to analysts' expectations of $3.42 million. Research analysts anticipate that Vera Therapeutics, Inc. will post -6.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wedbush dropped their target price on Vera Therapeutics from $34.00 to $29.00 and set a "neutral" rating on the stock in a report on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vera Therapeutics in a report on Thursday, October 15th. TD Cowen reaffirmed a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, September 15th. Guggenheim lowered their price objective on shares of Vera Therapeutics from $76.00 to $66.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Wall Street Zen raised shares of Vera Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Vera Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $74.93.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the firm's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the sale, the chief executive officer owned 235,244 shares of the company's stock, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company's research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera's lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.